References

Autoimmune diseases and atherosclerotic cardiovascular disease

10.1038/s41569-024-01045-7 · 2024 · External reference

Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases

10.1038/s41584-024-01149-x · 2024 · External reference

Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies

10.1093/cvr/cvab285 · 2021 · External reference

Role of antibodies and their specificities in atherosclerotic cardiovascular disease

10.1161/atvbaha.124.319843 · 2024 · External reference

Advancing research on regulatory autoantibodies targeting GPCRs: insights from the 5th international symposium

10.1016/j.autrev.2025.103855 · 2025 · External reference

Functional autoantibodies: definition, mechanisms, origin and contributions to autoimmune and non-autoimmune disorders

10.1016/j.autrev.2023.103386 · 2023 · External reference

Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases

10.1038/nrrheum.2017.134 · 2017 · External reference

Autoantibodies against the chemokine receptor 3 predict cardiovascular risk

10.1093/eurheartj/ehad666 · 2023 · External reference

Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis

10.1186/s13075-018-1545-8 · 2018 · External reference

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

10.1136/ard.2010.138461 · 2010 · External reference

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis

10.1136/annrheumdis-2016-209846 · 2017 · External reference

Antibodies to high-density lipoproteins are associated with inflammation and cardiovascular disease in rheumatoid arthritis patients

10.1016/j.trsl.2015.07.004 · 2015 · External reference

Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

10.1136/ard.61.6.554 · 2002 · External reference

Higher frequencies of age-associated B-cells in early arthritis are linked to atherosclerosis and immune circuits—a potential role as a biomarker for risk stratification

10.1093/rheumatology/keaf318 · 2025 · External reference

Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood

10.1093/nar/gkr424 · 2011 · External reference

Autoantibodies against C5aR1, C3aR1, CXCR3, and CXCR4 are decreased in primary Sjogren’s syndrome

10.1016/j.molimm.2020.12.027 · 2021 · External reference

Decreased endothelin receptor A autoantibody levels are associated with early ischaemic events in patients with giant-cell arteritis

10.1136/annrheumdis-2019-215341 · 2019 · External reference

Integrative analysis reveals the autoantibodyome neuroimmune signature of neurodegeneration

10.1016/j.isci.2026.114781 · 2026 · External reference

GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis

10.1038/s41467-018-07598-9 · 2018 · External reference

Decreased concentrations of C5a complement receptor antibodies are associated with relapse in eosinophilic granulomatosis with polyangiitis (EGPA)

10.1136/rmdopen-2024-005323 · 2025 · External reference

Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease

10.1371/journal.pone.0060726 · 2013 · External reference

Serum autoantibodyome reveals that healthy individuals share common autoantibodies

10.1016/j.celrep.2022.110873 · 2022 · External reference

CD4 + T cells promote the transition from hypertrophy to heart failure during chronic pressure overload

10.1161/circulationaha.113.007101 · 2014 · External reference

Beta-1-adrenergic receptor antibodies in acute coronary syndrome: is less sometimes more

10.3389/fcvm.2018.00170 · 2018 · External reference

Lowered anti-beta1 adrenergic receptor antibody concentrations may have prognostic significance in acute coronary syndrome

10.1038/s41598-019-51125-9 · 2019 · External reference

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

10.1136/annrheumdis-2016-209775 · 2017 · External reference

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome

10.1136/annrheumdis-2021-221733 · 2022 · External reference

Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications

10.1136/bmj.k1036 · 2018 · External reference

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients

10.1136/ard.2006.059980 · 2008 · External reference

Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis

10.1136/annrheumdis-2017-211735 · 2018 · External reference

CXCR3 regulates CD4+ T cell cardiotropism in pressure overload–induced cardiac dysfunction

10.1172/jci.insight.125527 · 2019 · External reference

High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis

10.1186/ar783 · 2003 · External reference

CXCR3 and CCR5 ligands in rheumatoid arthritis synovium

10.1006/clim.2000.4957 · 2001 · External reference

Role of chemokines CXCL9, CXCL10, CXCL11, and CXCR3 in the serum and minor salivary gland tissues of patients with Sjögren’s syndrome

10.1007/s10238-024-01401-4 · 2024 · External reference

Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis

10.1093/rheumatology/keab229 · 2021 · External reference

Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease

10.1038/s41584-023-00969-7 · 2023 · External reference

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register

10.1002/art.22809 · 2007 · External reference

Disease activity in rheumatoid arthritis and the risk of cardiovascular events

10.1002/art.39098 · 2015 · External reference

What makes antibodies against G protein-coupled receptors so special? A novel concept to understand chronic diseases

10.3389/fimmu.2020.564526 · 2020 · External reference

The role of CXCR3 and associated chemokines in the development of atherosclerosis and during myocardial infarction

10.3389/fimmu.2018.01932 · 2018 · External reference

CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus

10.1016/j.jaut.2015.07.001 · 2015 · External reference

Heterogeneity of the type I interferon signature in rheumatoid arthritis: a potential limitation for its use as a clinical biomarker

10.3389/fimmu.2017.02007 · 2018 · External reference